Compassionate Use of Eribulin for the Treatment of Advanced Breast Cancer Refractory to All Other Marketed Therapies.
Phase of Trial: Phase III
Latest Information Update: 23 Oct 2013
At a glance
- Drugs Eribulin (Primary)
- Indications Advanced breast cancer
- Focus Adverse reactions
- 04 Nov 2011 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 09 Dec 2010 Actual initiation date (Aug 2010) added as reported by ClinicalTrials.gov.
- 09 Dec 2010 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.